Is it necessary to do maximal androgenic blockade in the treatment of prostatic cancer?


Cite item

Full Text

Abstract

As the literature data give arguments both pro and contra wide use of maximal androgenic block (MAB) in the treatment of prostatic cancer, the authors studied MAB in 200 patients. They came to the conclusion that MAB can be applied in patients with symptoms of disseminated prostatic cancer as neoadjuvant therapy before prostatectomy and as neoadjuvant and adjuvant therapy in planning radiotherapy.

About the authors

B P Matveev

B V Bukharkin

References

  1. Buggins С., Hodges С. V. Studies on prostatic cancer. - I // Cancer Res. - 1941. - Vol. 1. - P. 293-297.
  2. Labrie F., Dupont A., Giguere M. et al. Advantages of combination therapy in previously untreated and treated patients with advanced prostatic cancer // J. Steroid Biochem. - 1986. - Vol. 25, N 5. - P. 877-883.
  3. Crawford E. D., Eisenberger M. A., McLeod D. G. et al. A. controlled trial of leuprolide with end without flutamide in prostatic carcinoma// N. Engl. J. Med. - 1989. - Vol. 321. - P. 419424.
  4. Denis L. J., Whelan P., Carnerio de Mourn J. L. et al. Goserelin acetate and flutamide versus bilateral orchiectomi: A Phase 111 EORTC trial (30853) // Urology. - 1993. - Vol. 42. P. 119-130.
  5. Janknegt R. A., Abbou С. С., Bartoletti R. et al. Orchiectomi and nilutamide or placebo as treatment of metastatis prostatic cancer in a multinational double-blind randomised trial // J. Urol. (Baltimore). - 1993. - Vol. 149. - P. 77-83.
  6. Bertagna C., De Gery A., Hucher M. et al. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomides double-blind trials (1056 patienst) // Br. J. Urol. - 1994. Vol. 73. - P. 396-402.
  7. Schellhammer P. F., Sharif R., Block N. L. et al. Bicalutamide or flutamide, each combined with luteinzing hormone-releasing hormone analogue (LHRH-A) therapy, in patients with stage D2 prostate cancer: final results of a multicenter, randomized trial // Abstr. from the Xlil-th Congress of the EAU. - Barselona, 1998. - P. 184.
  8. Eisenberger M., Thompson I., Tolcher A. et al. African american ethnic background is an independent and negative predictor of survival in metastatic prostatae cancer // J. Urol. (Baltimore) - 2000. - Vol. 163. - Suppl. - P. 56. - Abstr. 242.
  9. Ditionno H. et al. // J. Urol. (Baltimore). - 1998. - Vol. 159 N 5. - Suppl. - P. 130. - Abstr. 490.
  10. Fourcade R. O., Chalciain C., Poterre M. An open multicenter randomised study to compare the effect and safety of casodex 150 mg monotherapy with castrathion plus nilutamide in metastatic prostate cancer // Abstr. from the XIII-th Congress of the EAU. - Barselona, 1998. - P. 349.
  11. PCTCG, 2000. - The Lancet Vol. 355, Apil 129, 2000.
  12. Labrie F., Dupont A., Cusan L. et al. Downstaging of localized prostate cancer be neoadjuvant therapy with flutamide and lupron. The first control and randomized trial // Clin. Invest. Med. - 1993. - Vol. 16. - P. 449-509.
  13. Soloway M. S., Sharifl R., Wajsman Z. et al. for the Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgene blockade in clinical stage B2 (T2bNxM0) prostate cancer // J. Urol. (Baltimore). - 1995. - Vol. 154. - P. 424-428.
  14. Tyrrel С. J. Adjuvant and neoadjuvant hormonal therapy for prostate cancer // Eur. Urol. - 1999. - Vol. 36, N 6. - P. 549-558.
  15. Narayan P., Lowe B. A., Carrol P. R., Thompson I. M. Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage С carcinoma of the prostate // Br. J. Urol. - 1994. - Vol. 73. - P. 544-548.
  16. Oesterling J. E., Andrews P. E., Suman V. J. et al. Preoperative androgen deprivation therapy: Arteficial lowering of serum prostatic antigen without downstaging in the tumor //J. Urol. (Baltimore). - 1993. - Vol. 149. - P. 779-782.
  17. Myers R. P., Larson-Keller J. J., Bergstralh E. J. et al. Hormonal treatment at a time of radical retropubic prostatectomy for stage Dl prostate cancer: Results of long-term follow-up // Ibid. - 1992. - Vol. 147. - P. 910-915.
  18. Seay T. M., Blute M. L., Zincke H. Long term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and Early Androgen ablation // Ibid. - 1998. -Vol. 159. - P. 357-364.
  19. Lukka H., Warde P., Pickles T. et al. Controversies in prostate cancer radiotherapy: consensus development // Can. J. Urol. - 2001. - Vol. 8, N 4. - P. 1314-1322.
  20. Horwitz E. M., Winter К., Hanks G. E. et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy// Int. J. Radiat. Oncol. Biol. Phys. - 2001. - Vol. 49, N 4. - P. 947-956.
  21. Robnett T. J., Whittigton R., Malkowicz S. B. et al. Long-term use of combined radiation therapy and hormonal in the management of stage Dl prostate cancer//Ibid. - 2002. -Vol. 53, N 5. - P. 1146-1151.
  22. Zagars G. K., Pollack A., von Eschenbach A. C. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer// Urology. - 2001. - Vol. 58, N 2. - P. 233-239.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies